Printer Friendly

Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer.

M2 PHARMA-April 10, 2014-Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer

(C)2014 M2 COMMUNICATIONS

Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) disclosed on Thursday the termination of the license of its AVERSION Technology to Pfizer.

Following the immediate cancellation of the letter license agreement, Pfizer's returns its FDA approved Oxecta (oxycodone HCl) product to Acura Pharmaceuticals.

The AVERSION Technology reportedly utilises a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.

Under the letter agreement, Acura will make a one-time payment of USD2.0m to Pfizer.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 10, 2014
Words:104
Previous Article:Karyopharm Therapeutics signs preferred provider agreement with Clinipace Worldwide.
Next Article:PuraMed BioScience announces development of its first cannabinoid-based medicine in mental health.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters